Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5495-5501

  Fallarino, F ^a   Grohmann, U ^a   Bianchi, R ^a   Vacca, C ^a   Fioretti, M C ^a   Puccetti, P ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; LYMPHOCYTE CLONE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR IMMUNOLOGY;

EID: 0034669956     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5495     Document Type: Article

References (43)

1. Cancer vaccines
2. + T cell responses in antitumor immunity
3. + cytotoxic T-cell responses during chronic viral infection
4. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
5. + T lymphocytes
6. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
7. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
8. + T cell reactivity to a model tumor antigen
9. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic- DBA/2 mice
10. Mouse tumor rejection antigens P815A and P815B: Two epitopes carried by a single peptide
11. Tumor antigens recognized by T lymphocytes
12. - or helper peptides in priming for skin test reactivity to a P815AB-related peptide
13. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide
14. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells
15. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state
16. IL-12 acts directly on DC to promote nucelar localization of NF-κB and primes DC for IL-12 production
17. Immunogenicity of tumor peptides: Importance of peptide length and stability of peptide/MHC class II complex
18. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
19. Selection of a highly transfectable variant from mouse mastocytoma P815
20. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL
21. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice
22. Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization
23. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28
24. + T cell reactivity
25. + cytotoxic T-lymphocyte activation in mice
26. T cell defined tumor antigens
27. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
28. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2L(d) and is recognized by cytotoxic T lymphocytes against mouse tumor P815
29. + T cells in the antitumor immune response
30. Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation
31. - dendritic cells to enhance presentation of a tumor peptide in vivo
32. + T-helper and a T-killer cell
33. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
34. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
35. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen
36. + anti-tumor T cells requires tumor expression of cell surface class II molecules
37. - T cells: Tumor eradication does not require participation of cytotoxic T cells
38. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class I negative tumors
39. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes
40. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
41. Cytotoxic T lymphocytes to a nonmutated tumor rejection antigen P1A: Normal development but restrained effector function in vivo
42. Interleukin-12: A proinflammatory cytokine with immuno-regulatory functions that bridges innate resistance and antigen specific adaptive immunity
43. + subset